Evidence map›Paper›PMID 39985630›Full record

ArticleNeurology and therapy2025

A Multi-omics Framework Based on Machine Learning as a Predictor of Cognitive Impairment Progression in Early Parkinson's Disease.

Yang Luo, YaQin Xiang, JiaBin Liu, YuXuan Hu, JiFeng Guo

Abstract read
In one paragraph

Article in Neurology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Semi-supervised ensemble learning with interval type-2 fuzzy-rough sets for Parkinson's disease prediction from multi-omics.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Redefining Non-Motor Symptoms in Parkinson's Disease.Journal of personalized medicine · 2025
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yang LuoDepartment of Neurology, XiangYa Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, Hunan, China.
YaQin XiangDepartment of Neurology, XiangYa Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, Hunan, China.
JiaBin LiuDepartment of Neurology, XiangYa Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, Hunan, China.
YuXuan HuDepartment of Neurology, XiangYa Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, Hunan, China.
JiFeng GuoDepartment of Neurology, XiangYa Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, Hunan, China. guojifeng@csu.edu.cn.ORCID http://orcid.org/0000-0002-3658-3928

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCognitive impairment (CI) is a common non-motor symptom of Parkinson's disease (PD). However, the diagnosis and prediction of CI progression in PD remain challenging. We aimed to explore a multi-omics framework based on machine learning integrating comprehensive radiomics, cerebrospinal fluid biomarkers, and genetics information to identify CI progression in early PD.

methodsPatients were first diagnosed with PD without CI at baseline. According to whether CI progressed within 5 years, patients were divided into two groups: PD without CI and PD with CI. Radiomics signatures were extracted from patients' T1-weighted MRI. We used machine learning methods to construct radiomics, hybrid, and multi-omics models in the training set and validated the models in the testing set.

resultIn the two groups, we found 7, 23, and 25 radiomics signatures with significant differences in the parietal, temporal, and frontal lobes, respectively. The radiomics model using the 25 signatures of the frontal lobe had an accuracy of 0.833 and an AUC (area under the curve) of 0.879 to predict CI progression. In addition, the hybrid model fused with the cerebrospinal fluid Aβ level had an accuracy of 0.867 and an AUC of 0.916. In our study, the multi-omics model showed the best predictive performance. The accuracy of the multi-omics model was 0.900, and the average AUC value after five-fold cross-validation was 0.928.

conclusionRadiomics signatures have a recognition effect in the CI progression in early PD. Multi-omics frameworks combining radiomics, cerebrospinal fluid biomarkers, and genetic information may be a potential predictor of CI progression in PD.

Indexed as

Cerebrospinal fluidCognitive impairmentMachine learningMagnetic resonance imagingParkinson’s diseaseWhole genome sequencing

Identifiers

PMID39985630
PMCPMC11906927

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.